Pharmaceuticals
Continuing the Resplendence with 20 Years' Glory, CPhI China Welcomes the Golden Year of Chinese Pharma
SHANGHAI, Dec. 3, 2019 /PRNewswire/ -- As a world-renowned vertical trade and exchange event of the pharmaceutical industry, CPhI & P-MEC China 2020 will take place at Shanghai New International Expo Centre (SNIEC)June 22-24, 2020. The exhibition will reach a scale of 210,000m2, facilitate over 3...
2019-12-03 16:54
2454
New Early Breast Cancer Drug Approved by Singapore Health Sciences Authority
* NERLYNX® (neratinib) now approved in Singapore for HER2+ breast cancer patients following adjuvant trastuzumab-based therapy * NERLYNX is the first therapy in the Specialised Therapeutics' portfolio approved inSE Asia * Five-year follow up data show NERLYNX reduces risk of invasive disease...
2019-12-03 05:30
1202
Innovent Presents Co-developed Cancer-Fighting Tyvyt(R) (Sintilimab Injection) at CIIE 2019 with Eli Lilly
SUZHOU, China, Nov. 28, 2019 /PRNewswire/ -- Innovent Biologics (01801.HK), a multinational biopharmaceutical company, and Eli Lilly and Company presented their co-developed Tyvyt® (generic name: sintilimab injection), a fully human anti-programmed cell death protein 1 (anti-PD-1) monoclonal anti...
2019-12-02 09:37
5288
Innovent Biologics Announces FDA Acceptance of NDA for Pemigatinib in Patients with Previously Treated, Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusions or Rearrangements
SUZHOU, China, Dec. 2, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today a...
2019-12-02 08:00
3396
National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) for Breast Cancer Indication
SHENZHEN, China, Nov. 29, 2019 /PRNewswire/ -- On November 29, 2019, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company's lead innovative product Epidaza® (Chidamide), an oral subtype-selective histone deacetylase (HDAC) inhib...
2019-11-29 20:22
4090
Ascletis successfully obtained Pharmaceutical Trade License and GSP Certificate, formed a Complete Commercial Layout
HANGZHOU, China and SHAOXING, China, Nov. 29, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that Ascle...
2019-11-29 08:00
2730
Tyvyt (Sintilimab Injection), an Innovative PD-1 Inhibitor Jointly Developed by Innovent and Lilly, is Included in the New Catalogue of National Reimbursement Drug List (NRDL)
SUZHOU, China, Nov. 28, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today jointly announced...
2019-11-28 12:10
4495
Mundipharma CEO Raman Singh Wins Executive of The Year at SBR Management Excellence Awards
SINGAPORE, Nov. 28, 2019 /PRNewswire/ -- Mundipharma CEO, Raman Singh has been named Executive of the Year for the third year running by the Singapore Business Review's (SBR) Management Excellence Awards, held at Conrad Centennial Singapore on 26 November. SBR's Management Excellence Awards hono...
2019-11-28 12:00
3850
Pfizer Unveils Positive Results from Asian Subgroup Analysis of ARCHER 1050
HONG KONG, Nov. 28, 2019 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) today announced the efficacy and tolerability results from the subgroup analysis of Asian patients enrolled in the ARCHER 1050, a randomized, multicenter, multinational, open-label Phase 3 study evaluating the efficacy of VIZIMPRO® ...
2019-11-28 00:34
8952
Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-PD-1/HER2 Bispecific Antibody in China
SUZHOU, China, Nov. 27, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today ...
2019-11-27 07:50
3604
New Study by TauRx Shows a Minimum Dose of Hydromethylthionine Could Slow Cognitive Decline and Brain Atrophy in Mild-to-moderate Alzheimer's Disease
ABERDEEN, Scotland and SINGAPORE, Nov. 27, 2019 /PRNewswire/ -- In a paper published in today's online issue of theJournal of Alzheimer's Disease (DOI 10.3233/JAD-190772), TauRx has reported unexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels ...
2019-11-27 02:31
1710
Japan and Singapore Grant CRISPR Patents to Merck
- Merck now holds 22 CRISPR-related patents worldwide across nine different geographies - Patents cover Paired Cas9 Nickase CRISPR genome-editing technology to advance gene therapy and research DARMSTADT, Germany, Nov. 26, 2019 /PRNewswire/ -- Merck, a leading science and technology company, to...
2019-11-26 21:00
2171
Xinhua Silk Road: Er-Kang highly recognized for "going global" achievements in Cambodia
PHNOM PENH, Cambodia, Nov. 25, 2019 /PRNewswire/ -- Hunan Er-Kang (Cambodia) Investment Co., Ltd., an overseas arm ofChina's Hunan Er-Kang Pharmaceutical Co., Ltd. (300267.SZ), has recently received a delegation of Communist Party led by Du Jiahao, Secretary of the CPC Hunan Provincial Committee,...
2019-11-25 18:16
1661
Pfizer Unveils Positive Results from Asian Subgroup Analysis of ARCHER 1050
SINGAPORE, Nov. 25, 2019 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) today announced the efficacy and tolerability results from the subgroup analysis of Asian patients enrolled in the ARCHER 1050, a randomized, multicenter, multinational, open-label Phase 3 study evaluating the efficacy of VIZIMPRO® ...
2019-11-25 08:15
2182
Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference
SYDNEY, Nov. 25, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share with investors interim data from its ongoing phase II study of GDC-0084 in glioblastoma, the most common and most aggressive form of...
2019-11-25 07:00
2140
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
5310
